Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.
Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.
Department of Diabetes Technology, Tohoku University of Graduate School of Biomedical Engineering, Japan. Electronic address: katsu@trc.med.tohoku.ac.jp.
Katsunori
K
Nonogaki
Department of Diabetes Technology, Tohoku University of Graduate School of Biomedical Engineering, Japan.
Takao
T
Kaji
D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D001786:Blood Glucose / Q000032:analysis*; D018819:Dipeptidyl Peptidase 4 / Q000097:blood; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology; D004357:Drug Synergism; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009025:Morpholines / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D058828:Serotonin 5-HT4 Receptor Agonists / Q000494:pharmacology; D014498:Uracil / Q000031:analogs & derivatives* / Q000494:pharmacology
D001549:Benzamides; D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D009025:Morpholines; D010880:Piperidines; D058828:Serotonin 5-HT4 Receptor Agonists; D014498:Uracil; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4; C062720:mosapride; C520853:alogliptin
5-HT4 receptor agonist; Alogliptin; DPP-4 inhibitor; GLP-1; Glucose tolerance; Mosapride